A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.

Conditions: Triple Negative Breast Cancer Metastatic, Melanoma Metastatic, Colorectal Cancer Metastatic

Sex: All

Ages: 18 Years – 80 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 95

Sponsor: Fudan University

Summary

This study focuses on the treatment of liver metastases from three common cancers: colorectal cancer, triple-negative breast cancer and melanoma. Currently, there are limitations in the treatment of liver metastases of these cancers. Multimodal thermophysical ablation therapy can reshape the tumor microenvironment, release neoantigens, and act as an in-situ vaccine. On this basis, the combination of multimodal ablation with immunotherapeutic drugs such as pucotenlimab will be explored. The efficacy and safety of this combination therapy in patients with liver metastases of solid tumors will be investigated, with the expectation of breaking through the existing treatment limitations.

Eligibility Criteria

Inclusion Criteria i. Common eligibility criteria for all cohorts: 1\. Age between 18-80 years,gender not limited; 2. Patients with hepatic lesions amenable to ablation, all hepatic lesions \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06889610). StuddyBuddy aggregates publicly available trial information.